NCT05426421 (LoDoCA) is a clinical trial in HIV, sponsored by Swiss Tropical & Public Health Institute.

Who is sponsoring NCT05426421?

NCT05426421 is sponsored by Swiss Tropical & Public Health Institute.

Is NCT05426421 still recruiting?

NCT05426421 is currently completed. Last updated 13 January 2025.

Last reviewed 2025-01-13 · How we verify

NCT05426421: LoDoCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV

Completed Last updated 13 January 2025

What this trial tests

trial in HIV in 258 participants. Completed in 20 September 2023.

Timeline

11 July 2022

Primary endpoint
20 September 2023

20 September 2023

Quick facts

Lead sponsor	Swiss Tropical & Public Health Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	258
Start date	11 July 2022
Primary completion	20 September 2023
Estimated completion	20 September 2023
Sites	1 location across Lesotho

Conditions studied

HIV — all drugs for HIV →

Sponsor

Swiss Tropical & Public Health Institute

Who can join

Under 18, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dolutegravir-based antiretroviral therapy is set to be increasingly replace ritonavir-boosted lopinavir-based regimens for the treatment of paediatric HIV. This prospective cohort study aims to compare tolerability, adverse effects, and virological outcomes between the two regimen types using a before-after design. The study is conducted in Lesotho, southern Africa, and includes children and adolescents transitioning from ritonavir-boosted lopinavir-based to dolutegravir-based antiretroviral therapy. It aims to provide detailed information on treatment tolerability and to inform paediatric treatment programmes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Special Issue: Abstract Supplement HIV Glasgow 10-13 November 2024, Glasgow, UK/Virtual.
· 2024 · cited 8× · PMID 39513741 · DOI 10.1002/jia2.26370
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV.
Blankenberger J, Devendra A, Bakaya M, Lee T, et al · · 2026 · PMID 41467721 · DOI 10.1097/qad.0000000000004432

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Swiss Tropical & Public Health Institute trials

Trials by the same sponsor.

NCT06606860 — Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets · Phase 1 · completed
NCT06373835 — Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis · Phase 2 · completed
NCT06304831 — Use of Facility Ratings to Improve Satisfaction With Heath Care for Children · NA · completed
NCT05644067 — Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic C · Phase 1 · completed
NCT06648603 — Citizen Action for Sustainable Dengue Control in Sub-Saharan Africa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05426421 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Tropical & Public Health Institute
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05426421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing